RU2009123656A - METHOD FOR PRODUCING GENETICALLY MODIFIED CELLS MEDICINAL PRODUCT AND ITS APPLICATION - Google Patents
METHOD FOR PRODUCING GENETICALLY MODIFIED CELLS MEDICINAL PRODUCT AND ITS APPLICATION Download PDFInfo
- Publication number
- RU2009123656A RU2009123656A RU2009123656/10A RU2009123656A RU2009123656A RU 2009123656 A RU2009123656 A RU 2009123656A RU 2009123656/10 A RU2009123656/10 A RU 2009123656/10A RU 2009123656 A RU2009123656 A RU 2009123656A RU 2009123656 A RU2009123656 A RU 2009123656A
- Authority
- RU
- Russia
- Prior art keywords
- genetically modified
- cells
- drug
- modified cells
- gdnf
- Prior art date
Links
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
1. Способ получения лекарственного препарата генетически модифицированных клеток и его применения, заключающийся в том, что получают двухкассетную генетическую плазмидную конструкцию pBud-VEGF-GDNF, содержащую фрагменты ДНК, кодирующие VEGF и GDNF, из биологической ткани человека выделяют мононуклеарные клетки, выделенные клетки генетически модифицируют генетической конструкцией pBud-VEGF-GDNF, генетически модифицированные клетки культивируют, концентрируют, очищают от культуральной среды, ресуспензируют, анализируют генетически модифицированные клетки на количество, концентрацию и жизнеспособность, по результатам анализа определяют оптимальную терапевтическую дозу генетически модифицированных клеток и получают лекарственный препарат генетически модифицированных клеток. ! 2. Лекарственный препарат по п.1 применяют для лечения нейродегенеративных заболеваний. !3. Лекарственный препарат по п.1 замораживают для хранения и последующего применения. 1. A method for producing a drug of genetically modified cells and its use, which consists in the production of a two-cassette genetic plasmid construct pBud-VEGF-GDNF containing DNA fragments encoding VEGF and GDNF, mononuclear cells are isolated from human biological tissue, isolated cells are genetically modified pBud-VEGF-GDNF genetic construct, genetically modified cells are cultured, concentrated, purified from the culture medium, resuspended, genetically modified are analyzed cells for the number, concentration and viability, according to the results of the analysis, the optimal therapeutic dose of genetically modified cells is determined and a drug of genetically modified cells is obtained. ! 2. The drug according to claim 1 is used to treat neurodegenerative diseases. ! 3. The drug according to claim 1 is frozen for storage and subsequent use.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2009123656/10A RU2431669C2 (en) | 2009-06-23 | 2009-06-23 | Method for producing preparation of genetically modified cells |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2009123656/10A RU2431669C2 (en) | 2009-06-23 | 2009-06-23 | Method for producing preparation of genetically modified cells |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2009123656A true RU2009123656A (en) | 2010-12-27 |
RU2431669C2 RU2431669C2 (en) | 2011-10-20 |
Family
ID=44055347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2009123656/10A RU2431669C2 (en) | 2009-06-23 | 2009-06-23 | Method for producing preparation of genetically modified cells |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2431669C2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2527169C2 (en) * | 2012-10-15 | 2014-08-27 | Федеральное государственное бюджетное учреждение науки Институт биологии гена Российской академии наук (ИБГ РАН) | GENETIC CONSTRUCT CONTAINING hGDNF CONTROLLED BY TEMPERATURE-SENSITIVE PROMOTOR FOR REGULATED NEUROTROPHIC FACTOR EXPRESSION IN MAMMALIAN CELLS AND BODIES DIRECTLY |
RU2557385C1 (en) * | 2014-06-18 | 2015-07-20 | Общество с ограниченной ответственностью "НекстГен" | Codon-optimised sequences and pharmaceutical composition for recovery of blood vessels |
RU2595377C2 (en) * | 2014-10-24 | 2016-08-27 | Общество с ограниченной ответственностью "АптаНова" | GENETIC NUCLEOTIDE SEQUENCES OF ARTIFICIALLY MODIFIED GDNF WITH DELETED pro-REGION, PRODUCT OF WHICH HAS IMPROVED PROPERTIES NEURAL INDUCTOR AND STIMULATOR OF FORMATION OF NEURAL PROCESSES, SUITABLE FOR THERAPY OF NEURAL INJURIES, ISCHEMIC STROKES AND NEURODEGENERATIVE DISEASES, EXPRESSION VECTOR, MODIFIED WITH GDNF |
RU2612497C2 (en) | 2015-05-26 | 2017-03-09 | Общество с ограниченной ответственностью "НекстГен" | Optimized nucleotide sequence and pharmaceutical compositions based thereon with sustained vegf transgene expression |
RU2716013C2 (en) * | 2019-05-27 | 2020-03-05 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации | Method for preparing a cell-mediated gene therapy agent and a cell-mediated gene therapy agent |
-
2009
- 2009-06-23 RU RU2009123656/10A patent/RU2431669C2/en active
Also Published As
Publication number | Publication date |
---|---|
RU2431669C2 (en) | 2011-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yu-Taeger et al. | Intranasal administration of mesenchymal stem cells ameliorates the abnormal dopamine transmission system and inflammatory reaction in the R6/2 mouse model of Huntington disease | |
RU2009123656A (en) | METHOD FOR PRODUCING GENETICALLY MODIFIED CELLS MEDICINAL PRODUCT AND ITS APPLICATION | |
MY151979A (en) | Method for producing mesenchymal stem cells from human pluripotent stem cells, and mesenchymal stem cells produced by same | |
WO2011097181A3 (en) | Compositions and methods for re-programming cells without genetic modification for treatment of neurological disorders | |
WO2013074059A3 (en) | Cytosine deaminase modulators for enhancement of dna transfection | |
BRPI0415563A (en) | method for treating parkinson's disease, use of a viral vector, viral expression vector, pharmaceutical composition, isolated host cell, packaging cell line, chimeric non-human mammal, implantable cell culture device, biocompatibly capsule, method for treatment of a nervous system disease, mammalian cell, and, method for producing neurturin or a functional equivalent thereof | |
JP2018512440A5 (en) | ||
WO2013126590A3 (en) | Pharmaceutical composition comprising cd34+ cells | |
Klimovich et al. | New frontiers in peripheral nerve regeneration: concerns and remedies | |
Chen et al. | Nanobiotechnology and nanomedicine: small change brings big difference | |
JP2016094460A (en) | Composition and method for treatment of neurodegenerative diseases or disorders comprising electromagnetically irradiated yeast, and use thereof | |
UY29544A1 (en) | TREATMENT OF DISEASES USING AN IMPROVED REGULATED EXPRESSION SYSTEM | |
Khokhlov et al. | Pilot study of a potential geroprotector,“Quinton Marine Plasma,” in experiments on cultured cells | |
CN102218146B (en) | ShRNA (Short Hairpin Ribonucleic Acid) kit for treating animal model suffered from alzheimer disease | |
RU2009133970A (en) | METHOD FOR PRODUCING GENETICALLY MODIFIED CELLS MEDICINAL PRODUCT AND ITS APPLICATION | |
CN105670999A (en) | MDS (myelodysplastic syndrome) transfection leukocyte line with capacity of stable expression of GFP (green fluorescent protein) | |
CN103558392B (en) | A kind of effect of the antiatherosclerotic based on inflammatory reaction evaluation method | |
CN105779349B (en) | A kind of dissolution pond advantage dinoflagellate-Scrippsiella trochoidea Bacillus cereus strain JZBC1 and its application | |
CN110172463A (en) | Application of the migratory locusts Knickkopf 3-5 ' gene dsRNA in control of insect | |
RU2016102172A (en) | THERAPY AND METHOD OF INTRA-TUMOR INTRODUCTION OF CYTOTOXIC T-LYMPHOCYTES AND / OR NKT CELLS WITH ANTIBODY AGAINST TNF AND / OR ANTIBODY AGAINST IL-10 | |
WO2008121016A8 (en) | Oncological disease treating method | |
CN103695468A (en) | Method for expressing EGF-TCSKDEL fusion protein by bombyx mori baculovirus Bac-to-Bac system | |
Winter et al. | The future of genetic engineering in biotechnology | |
ATE527342T1 (en) | CELL CULTURE WITH NM23, NM23 COMPREHENSIVE CELL CULTURE MEDIA AND THERAPEUTIC USE OF CELLS CULTURED IN THE PRESENCE OF NM23 | |
Singh et al. | Bio-nanotechnology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PD4A | Correction of name of patent owner |